Characterization of novel small non-coding RNAs and their modifications in bladder cancer using an updated small RNA-seq workflow

Zhangli Su; Ida Monshaugen; Arne Klungland; Rune Ougland; Anindya Dutta

doi:10.3389/fmolb.2022.887686

Characterization of novel small non-coding RNAs and their modifications in bladder cancer using an updated small RNA-seq workflow

Front Mol Biosci. 2022 Jul 18:9:887686. doi: 10.3389/fmolb.2022.887686. eCollection 2022.

Authors

Zhangli Su^{1

2}, Ida Monshaugen^{3

4

5}, Arne Klungland^{3

6}, Rune Ougland^{3

5}, Anindya Dutta^{1

2}

Affiliations

¹ Department of Genetics, University of Alabama at Birmingham, Birmingham, AL, United States.
² Department of Biochemistry and Molecular Genetics, School of Medicine, University of Virginia, Charlottesville, VA, United States.
³ Department of Microbiology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
⁴ Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.
⁵ Department of Surgery, Baerum Hospital Vestre Viken Hospital Trust, Gjettum, Norway.
⁶ Department of Biosciences, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway.

Abstract

Background: Bladder cancer (BLCA) is one of the most common cancer types worldwide. The disease is responsible for about 200,000 deaths annually, thus improved diagnostics and therapy is needed. A large body of evidence reveal that small RNAs of less than 40 nucleotides may act as tumor suppressors, oncogenes, and disease biomarkers, with a major focus on microRNAs. However, the role of other families of small RNAs is not yet deciphered. Recent results suggest that small RNAs and their modification status, play a role in BLCA development and are promising biomarkers due to their high abundance in the exomes and body fluids (including urine). Moreover, free modified nucleosides have been detected at elevated levels from the urine of BLCA patients. A genome-wide view of small RNAs, and their modifications, will help pinpoint the molecules that could be used as biomarker or has important biology in BLCA development. Methods: BLCA tumor tissue specimens were obtained from 12 patients undergoing transurethral resection of non-muscle invasive papillary urothelial carcinomas. Genome-wide profiling of small RNAs less than 40 bases long was performed by a modified protocol with TGIRT (thermostable group II reverse transcriptase) to identify novel small RNAs and their modification status. Results: Comprehensive analysis identified not only microRNAs. Intriguingly, 57 ± 15% (mean ± S.D.) of sequencing reads mapped to non-microRNA-small RNAs including tRNA-derived fragments (tRFs), ribosomal RNA-derived fragments (rRFs) and YRNA-derived fragments (YRFs). Misincorporation (mismatch) sites identified potential base modification positions on the small RNAs, especially on tRFs, corresponding to m¹A (N¹-methyladenosine), m¹G (N¹-methylguanosine) and m² ₂G (N², N²-dimethylguanosine). We also detected mismatch sites on rRFs corresponding to known modifications on 28 and 18S rRNA. Conclusion: We found abundant non-microRNA-small RNAs in BLCA tumor samples. Small RNAs, especially tRFs and rRFs, contain modifications that can be captured as mismatch by TGIRT sequencing. Both the modifications and the non-microRNA-small RNAs should be explored as a biomarker for BLCA detection or follow-up.

Keywords: RNA modification; YRNA-derived fragment; bladder cancer; non-coding RNA; rRNA-derived fragment; small RNA; tRNA-derived fragment.

Abstract

Grants and funding